XNASALLR
Market cap4mUSD
Dec 26, Last price
1.08USD
1D
6.40%
1Q
-50.91%
IPO
-100.00%
Name
Allarity Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L-25.89%
CFO
-13m
L-24.21%
Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 17,929 | 17,012 | 26,662 | ||
Unusual Expense (Income) | |||||
NOPBT | (17,929) | (17,012) | (26,662) | ||
NOPBT Margin | |||||
Operating Taxes | (717) | (1,521) | 133 | ||
Tax Rate | |||||
NOPAT | (17,212) | (15,491) | (26,795) | ||
Net income | (11,901) -25.89% | (16,058) -39.74% | (26,648) 425.29% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 13,644 | (1,511) | 32,125 | ||
BB yield | 0.00% | ||||
| Debt | |||||
Debt current | 1,300 | 2,652 | 98 | ||
Long-term debt | 1,091 | 1,095 | |||
Deferred revenue | (1,432) | ||||
Other long-term liabilities | 1,432 | 7,181 | |||
Net debt | 1,134 | 1,714 | (18,712) | ||
| Cash flow | |||||
Cash from operating activities | (12,745) | (16,817) | (15,050) | ||
CAPEX | (18) | ||||
Cash from investing activities | 791 | 1,000 | |||
Cash from financing activities | 10,995 | (1,311) | 33,819 | ||
FCF | (9,970) | (11,822) | (28,835) | ||
| Balance | |||||
Cash | 166 | 2,029 | 19,555 | ||
Long term investments | 350 | ||||
Excess cash | 166 | 2,029 | 19,905 | ||
Stockholders' equity | (93,120) | (81,266) | (65,650) | ||
Invested Capital | 91,669 | 86,850 | 92,641 | ||
ROIC | |||||
ROCE | 1,783.98% | ||||
| EV | |||||
Common stock shares outstanding | 1,990,748 | ||||
Price | 330.66 -99.87% | 246,792.00 -97.17% | 8,714,580.00 | ||
Market cap | 658,260,734 | ||||
EV | 658,263,610 | ||||
EBITDA | (17,892) | (16,952) | (26,556) | ||
EV/EBITDA | |||||
Interest | 498 | 223 | 499 | ||
Interest/NOPBT | |||||